Patients with vascular malformations (VAMs) and vascular overgrowth syndromes have lower health-related quality of life (HRQoL) attributable to social stigmatization, poor mental health, severity, and pain. However, the factors that contribute to this decreased HRQoL are not clear.
V ascular malformations (VAMs) are abnormalities in blood vessel morphogenesis with an overall prevalence of approximately 1.2% to 1.5% among children 1, 2 but generally have a lifelong presentation. Malformations may include capillary malformation, venous malformation (VM), lymphatic malformation (LM), or arteriovenous malformation with or without overgrowth. Complications are common and may include thrombophlebitis, bleeding, ulcers, pain, and impairment of function attributable to VM involvement of joints, bones, or muscles. 3 Patients with VAMs have a lower health-related quality of life (HRQoL) than the general population. [4] [5] [6] The term HRQoL is used to describe an overall state of well-being and satisfaction with life, encompassing multiple dimensions, such as general health, society, work, and friendship. Factors such as social stigmatization, mental health, location, severity, and pain have been reported to affect the quality of life (QoL) in those with VAMs. 5, 7, 8 However, the factors that contribute to this decreased QoL are largely unknown. Several studies 5, 6, 9 have examined HRQoL in children and adults with VAMs, but their HRQoL assessments have been largely inconclusive because of the use of nonvalidated QoL instruments. The goal of this systematic review was to obtain an accurate quantitative HRQoL measurement from patients with VAMs using only studies with validated HRQoL instruments and to compare this cohort with the US general population.
Methods
This systematic review and meta-analysis study was performed according to the MOOSE (Meta-analyses of Observational Studies in Epidemiology) guidelines. 10 The PICOS (patient, problem, or population; intervention; comparison, control, or comparator; and outcome) framework was used to define the population (people of all ages), intervention or exposure (VAMs), comparison group (general US population vs those with VAMs), outcomes (HRQoL), and study (cohort and cross-sectional). The objective was to compare the HRQoL of patients with VAMs with that of the general US population using only studies with validated HRQoL instruments.
Search System Methods
An experienced librarian (Patricia Erwin, MLS) was consulted to aid in designing a search strategy to include all studies on VAMs and HRQoL. A search was performed in the Ovid MEDLINE, Embase, PsycINFO, CINAHL, and Scopus electronic databases for English-language articles published between 1946 and March 31, 2017. Two of us (H.L.N. and G.F.B.) screened the title and abstract of all studies found through the search and afterward manually examined the references from the included articles for additional articles that the electronic search may have missed ( Figure 1 ).
Inclusion and Exclusion Criteria
All VAM studies that used validated HRQoL instruments published in the English language were included. Studies that examined the HRQoL in relation to a treatment modality were included if these studies reported the HRQoL score of patients with VAMs before starting treatment. Case reports, review articles, unpublished studies, publications not in the English language, abstracts, and studies about the development of new QoL instruments were excluded.
Study Quality Assessment
The Newcastle-Ottawa Scale (NOS) 11 was used to assess the risk of bias by 2 of us (H.L.N. and G.F.B.
). An adapted version of the scale was used in the cross-sectional studies. The NOS has 3 domains: selection, comparability, and outcome. The selection domain can have a maximum of 4 stars, the comparability domain can have 2 stars, and the outcome domain can have 3 stars for a combined total of 9 stars across all domains. A higher number of stars is associated with higher-quality articles and lower risks of bias ( Table 1) .
Data Extraction
Data were extracted from the studies by 2 of us (H.L.N. and G.F.B.). Extracted data include authors, year of publication, country of study, study design, type of VAM, sample size, mean age, and HRQoL instruments and their scores. In the case that an eligible study lacked the necessary data, the first, second, and corresponding authors were contacted to obtain this information.
role physical (problems with work or other daily activities as a result of physical health), bodily pain (pain scale and how it interferes with activities), general health (subjective overall health perception), vitality (energy level, how easily one gets tired), social functioning (interference of normal social activities attributable to physical and emotional problems), role emotional (problems with work or other daily activities as a result of emotional problems), and mental health (feelings of happiness, peacefulness, nervousness, or depression). Scores of 0 to 100 are reported, with higher scores representing a better HRQoL.
10-Item Short-Form Health Survey
A generic parent-completed 10-Item Short-Form Health Survey 22 that assesses HRQoL in the past 4 weeks was used. The survey has been validated for patients between 5 and 17 years of age. Scores are reported as a physical and psychosocial health summary score of 0 to 100, with a higher score indicating better HRQoL.
Pediatric Quality of Life Inventory
A generic 21-to 23-item Pediatric Quality of Life Inventory 23 that assesses HRQoL in the following 4 domains during the previous month was used: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (3 of 5 items). The mean sum of the last 3 domains makes up the psychosocial health summary score, and the physical functioning score is the physical health summary score. Scores of 0 to 100 are reported, with a higher score indicating better HRQoL.
Dermatology Life Quality Index
The Dermatology Life Quality Index 24 was used to assess HRQoL on a scale of 30 points for patients older than 16 years during the previous week. Each item is scored on a 4-point Likert scale from 0 to 3. At the end, all items are summed to yield a total score of 0 through 30. Scores from 0 through 1 indicate no influence on the patient's life; 2 through 5, small influence on the patient's life; 6 through 10, moderate influence on the patient's life; 11 through 20, very large influence on the patient's life; and 21 through 30, extremely large influence on the patient's life.
Children's Dermatology Life Quality Index The Children's Dermatology Life Quality Index 25 was used to assess HRQoL in patients 4 through 16 years of age during the previous week. The index is scored from 0 through 30 points. Scores from 0 through 1 indicate no influence on the child's life; 2 through 6, small influence; 7 through 12, moderate influence; 13 through 18, very large influence; and 19 through 30, extremely large influence.
Skindex-29
Skindex-29 26 was used to assess HRQoL during the previous month using the following 3 domains: symptoms (7 items), emotions (10 items), and functioning (12 items). A total score is calculated by averaging the scores from the 3 domains. Each item is scored on a 5-point Likert scale: never, rarely, sometimes, often, or all the time. All responses are transformed to a linear scale from 0 to 100, with higher scores indicating lower HRQoL.
Statistical Analysis
The mean, SD, sample size, and 95% CIs were extracted or calculated for the 6 studies in the meta-analysis. The Dersimonian and Laird random-effects pooling method was used for the pooled analysis of the SF-36 scores of the 8 domains. 27 The random-effects model was chosen because these VAM studies measure the same outcome (SF-36 scores) but were conducted by separate groups from different countries; thus, there exists some degree of heterogeneity, which is more consistent with clinical situations. 
Results

Literature Search
A search of MEDLINE found 550 publications; Embase, 1597; Scopus, 1646; PsycINFO, 0; and CINAHL, 20. The total number of publications found was 3813, of which 1020 were duplicates. As a result, there were 2793 unique publications, and after the review of abstracts and titles, 59 studies met the inclusion criteria. Screening the references of these 59 studies yielded 2 more publications that were not in the computer search. The full texts of the 61 eligible studies were reviewed by 2 of us (H.L.N. and G.F.B.). In total, 11 studies were included in the analyses (5 in the qualitative analysis and 6 in the quantitative analysis) ( Figure 1 ).
Study Characteristics and Quality
The characteristics of each study are outlined in Table 2 .Ofthe 11 studies included in this systematic review, 6 were crosssectional studies and 5 were cohort studies. Four studies were from North America, 6 from Europe, and 1 from Japan. The 11 studies combined included 692 patients. The 6 studies that were included in the quantitative meta-analysis included 320 patients, whereas the 5 studies included in the qualitative synthesis included 372 patients. With use of the NOS, 5 studies received a 7-star rating, which denotes satisfactory-quality articles with low risks of bias, whereas the rest of the studies had substantial risks of bias. However, we believed that the 3 domains of the NOS did not capture risks of bias accurately in these studies. 30 Therefore, in addition to reporting the NOS score, we provided our own assessment of these studies' risks of bias based on sample size, inclusion and exclusion criteria, control for other comorbidities, survey response rate, patients who were lost to or unavailable for follow-up, statistical methods, and whether the research questions and the outcome were clearly defined. On the basis of our judgment, 8 studies were rated as having high or unclear risks of bias and 3 studies as having moderate risks of bias (Table 1) .
Quantitative Meta-analysis
The results of the meta-analysis included 6 studies 4, 7, 13, 14, 17, 19 and are given in Figure 2 and Figure 3 . One study 14 did not provide explicit SF-36 scores and SD values. Two attempts were made to contact the authors, and the second author replied that he was not able to provide the data. Thus, the scores were extracted from the graph, and the combined SDs from the 5 studies 4, 7, 13, 17, 19 were used because all 6 studies had similar pa- According to the Skindex-29 (higher scores denote worse HRQoL), patients with KTS had lower HRQoL in the symptoms domain than those without skin disease, those with vitiligo, and those with facial PWS but better HRQoL than those with psoriasis, pemphigus, eczema, epidermolysis bullosa, tinea, lichen sclerosus, cutaneous lupus erythematosus, dermatomyositis, and vulvodynia. For the emotions domain, patients with KTS had poorer HRQoL than patients without skin disease but better HRQoL than those with vitiligo, facial PWS, rosacea, acne vulgaris, morphea, psoriasis, pemphigus, eczema, epidermolysis bullosa, tinea, lichen sclerosus, cutaneous lupus erythematosus, dermatomyositis, and vulvodynia. Finally, patients with KTS had poorer HRQoL in the functioning domain than patients without skin disease, warts, and nonmelanoma skin cancer or actinic keratosis but better HRQoL than those with facial PWS, chronic hand dermatitis, pemphigus, eczema, epidermolysis bullosa, tinea, lichen sclerosus, cutaneous lupus erythematosus, dermatomyositis, and vulvodynia (eTable in the Supplement). Bodily pain results are statistically significant. VM indicates venous malformation.
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Discussion
The results of this systematic review and meta-analysis suggest that patients with VAMs have higher bodily pain than the general US population, which greatly influences HRQoL. This influence is likely in large part attributable to complications that result in significant morbidity in this population. 35 Of importance, patients with VAMs have lower SF-36 mental health scores, which represent overall mood and mental state, compared with the US general population. 21 Although specialists who care for patients with VAMs often focus on the pressing medical morbidities that are often present, evaluation of psychosocial and mental health should be an important component of care, with appropriate referrals for support and counseling made as indicated. A specific subset of patients with VAMs have KTS. In addition to the VMs and LMs, patients with KTS also have PWSs and overgrowth of bone or soft tissue, the latter of which can also pose challenging difficulties with physical health. This triad of findings has a significant influence on HRQoL. Those with KTS have lower scores in 5 of 8 SF-36 domains (physical functioning, role physical, general health, role emotion, and mental health) compared with the VAM cohort. This finding suggests that patients with KTS are more physically and mentally impaired compared with those with isolated VAMs. The KTS mental health score revealed no statistically significant difference vs the general US population but a statistically significant higher mental health score vs the VAM cohort. A possible explanation for this observation is that those who are born with KTS have developed resilience. In addition, robust patient advocacy groups currently exist for KTS, which may be helpful with the mental burden and resiliency. However, because this observation is based only on 1 European study, 17 it may not be generalizable to all patients with KTS. Nijsten et al 31 statistically categorized Skindex-29 scores to distinct stratification based on the influence on HRQoL. This study revealed that KTS had a moderate impairment on HRQoL and a similar HRQoL score to vitiligo, onychomycosis, alopecia areata, and facial PWSs (eTable in the Supplement). Although this appears to be reassuring, the Skindex-29 has only been validated for QoL assessment of patients with skin diseases and likely underestimates the influence of the extracutaneous involvement in patients with KTS. However, it may be inferred that the cosmetic appearance of KTS has a minimal influence on patients' HRQoL and that treatment can likely focus on alleviating functional impairment. In addition to severity of the disease, the location of VAMs can have an influence on HRQoL. Those with VMs and LMs of the head and neck have more difficulty with sleeping and daytime functioning than those with VMs and LMs at other locations, and as a result they have lower HRQoL. 12 This finding suggests that evaluating sleep hygiene and quality should be a focus when treating patients with head and neck VMs and LMs, which is often not a primary focus of those caring for these patients. Patients with facial PWSs had lower HRQoL scores across all domains of the Skindex-29 compared with the population without skin disease 8 (eTable in the Supplement). The emotions domain is influenced the most, followed by the functioning and the symptoms domain. The emotional influence of facial PWSs is similar to that of vitiligo, rosacea, epidermolysis bullosa, and psoriasis. 8 This finding confirms that visible skin aberration, such as PWSs, on a highly visible area of the body has an influence on a person's mental health, in accordance with prior studies.
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Strengths and Limitations
This systematic review has many strengths, particularly regarding methods. First, the search strategy was performed thoroughly with the consultation of an experienced librarian and is reproducible. Second, 2 of us screened for eligible studies, reviewed the full-text articles, performed quality assessments, and extracted the relevant data. Therefore, potential sources of biases and errors were minimized. Third, only studies that used validated HRQoL instruments were included, which resulted in a comprehensive analysis of HRQoL in patients with vascular anomalies with multiple findings that are meaningful and applicable to clinical practice.
There are several limitations regarding making inferences from this systematic review and meta-analysis. For nonrandomized, observational studies, the NOS is one of the few available tools to assess studies' risk of bias 37 and therefore is often used by many systematic reviews. Despite this, we and others have found that the NOS does not capture the nuances of the 11 studies adequately and therefore is an inaccurate indicator of risks of bias. 30,38,39 Therefore, any conclusions regarding articles' quality using NOS scores should be interpreted with caution. Second, there is significant heterogeneity among the 6 studies in this meta-analysis because VAM is an umbrella term that includes capillary malformation, VM, LM, arteriovenous malformation, and vascular overgrowth syndromes, all of which are heterogeneous in the presentation. We were unable to consider the severity, type, and location of the malformation on the body, time frame of diagnosis, treatments, other comorbidities and their severities, age distribution of those affected, and society differences in medical and mental health support in the analysis. Thus, it is possible that those with more severe VAMs or those who live in areas with less medical and mental health support may have even lower HRQoL. Furthermore, sampling bias may exist because those with more severe VAMs are more likely to get treatment and therefore are more likely to be enrolled in HRQoL studies. Finally, some of these studies have a small sample size of 30 or fewer patients [13] [14] [15] [16] 18 and a disproportionate female to male ratio; 13, 16 thus, they may not represent the wider population.
Conclusions
Patients with VAMs have more pain and greater mental stress than the US general population, findings that are influenced by the location of involvement. 
